Skip to content
Politically.com Search all
Menu

2025 · 1st Quarter (Jan 1 - Mar 31)

VIVEX BIOLOGICS

Filed by THE MCMANUS GROUP.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
1st Quarter - Report
Posted
Apr 21, 2025
Income
$50,000.00
Expenses
Not reported
Filing UUID
033b7ef3-e4d3-43bd-aed0-5ab59d8bddf1
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

Education on Human Cellular Tissue Products (HCTPs).

MMM · Medicare/Medicaid

Issues related to coverage of Human Cell & Tissue products, including Local Coverage Determination L39764- Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers. Issues related to coverage, including VIA Disc local coverage determination. LCD ID: L39962 - Coverage Indications, Limitations and/or Medical Necessity section to include non-coverage for all intervertebral disc injections for management of chronic low back pain.

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.